Heron Therapeutics Inc. (NASDAQ:HRTX)’s share price was down 1.8% during trading on Thursday . The stock traded as low as $20.68 and last traded at $20.80, with a volume of 297,659 shares changing hands. The stock had previously closed at $21.19.

Several equities analysts recently commented on HRTX shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, August 3rd. Jefferies Group restated a “buy” rating and set a $46.00 target price on shares of Heron Therapeutics in a research report on Wednesday, July 27th. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Leerink Swann restated a “buy” rating on shares of Heron Therapeutics in a research report on Monday, June 27th. Finally, Brean Capital restated a “buy” rating and set a $55.00 target price on shares of Heron Therapeutics in a research report on Friday, May 6th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $47.70.

The firm has a 50-day moving average of $18.13 and a 200-day moving average of $18.80.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.21. On average, equities analysts anticipate that Heron Therapeutics Inc. will post ($4.39) earnings per share for the current fiscal year.

In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of Heron Therapeutics stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total value of $2,330,000.00. Following the completion of the sale, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

An institutional investor recently bought a new position in Heron Therapeutics stock. Bank of Montreal Can bought a new position in Heron Therapeutics Inc. (NASDAQ:HRTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 112,720 shares of the biotechnology company’s stock, valued at approximately $3,010,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.